This is a competitive renewal of the Birmingham ACTU, established in 1992 at the UAB AIDS Outpatient (1917) Clinic, and is submitted in conjunction with the ACTG Group application led by Robert T. Schooley, MD (PI). The Birmingham ACTU has been a national leader in the development and implementation of clinical trials that link therapeutics and pathogenesis, a high priority of the ACTG recompetition. Investigators from UAB have assumed leadership positions within the ACTG and have played a pivotal role in the establishment and performance of the Group's Scientific Agenda. This application builds on the experience of the Birmingham ACTU and adds investigators from Emory University as important new contributors to the ACTG effort through the establishment of a subunit at the Ponce de Leon Clinic in Atlanta. The primary focus of the UAB/Emory ACTU is to: (i) Establish collaborative studies within the ACTG which focus on the clinical significance and therapeutic implications of recent insights into HIV pathogenesis elucidated at our site; (ii) Further development improved therapeutic approaches in the treatment of cytomegalovirus, mycobacterial, human papilloma virus, herpes-related viruses, mycoplasma, and cryptococcal disease, areas where UAB/Emory investigators have made critical contributions and have unique expertise; (iii) Improve access of women and minorities to ACTG-related clinical trials through the 1917 Women's Clinic and the Women's Clinic at the Ponce de Leon Center and through targeted outreach programs to HIV-infected African Americans, the most rapidly growing population of HIV-infected patients, especially in the Southeastern United States; and (iv) Contribute to the overall mission and Scientific Agenda of the ACTG through active participation in Group activities and provision of leadership within key administrative committees. Our current level of performance, scientific contributions, history of leadership within the Group, geographic location within the most rapidly growing population of newly acquired HIV disease (Southeastern United States), and our unique expertise in critical areas of the Group's scientific focus makes the UAB/Emory ACTU an ideal site for the conduct of clinical trials through the ACTG network.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI032775-08
Application #
2856001
Study Section
Special Emphasis Panel (SRC (82))
Program Officer
Batzold, Frederick
Project Start
1992-04-01
Project End
1999-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Lockman, Shahin; Hughes, Michael; Sawe, Fred et al. (2012) Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 9:e1001236
Ciaranello, Andrea L; Lockman, Shahin; Freedberg, Kenneth A et al. (2011) First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS 25:479-92
Boltz, Valerie F; Zheng, Yu; Lockman, Shahin et al. (2011) Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 108:9202-7
Haas, David W; Koletar, Susan L; Laughlin, Laura et al. (2009) Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 50:290-3
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J et al. (2008) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47:459-66
Twigg Iii, Homer L; Weiden, Michael; Valentine, Fred et al. (2008) Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 197:109-16
Kilby, J Michael; Lee, Ha Youn; Hazelwood, J Darren et al. (2008) Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. AIDS 22:957-62
Riddler, Sharon A; Jiang, Hongyu; Tenorio, Allan et al. (2007) A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 12:531-41
Acosta, Edward P; Kendall, Michelle A; Gerber, John G et al. (2007) Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 51:3104-10

Showing the most recent 10 out of 71 publications